IBT:CA:CDX-IBEX Technologies Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 1.43

Change

0.00 (0.00)%

Market Cap

USD 3.58M

Volume

0.16M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ibex Technologies Inc through its subsidiaries manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays used in osteoarthritis research.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.09 (+4.46%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

-0.12 (-5.94%)

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

+0.18 (+18.56%)

USD 0.02B
CZO:CA Ceapro

+0.02 (+8.33%)

USD 0.02B
KNE:CA Kane Biotech Inc

-0.01 (-3.85%)

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

+0.45 (+12.43%)

USD 0.02B

ETFs Containing IBT:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.17% 52% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.17% 52% F 74% C
Trailing 12 Months  
Capital Gain 70.24% 96% N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.24% 96% N/A 93% A
Trailing 5 Years  
Capital Gain 694.44% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 694.44% 94% A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 76.95% 96% N/A 90% A-
Dividend Return 76.95% 96% N/A 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.86% 50% F 51% F
Risk Adjusted Return 160.79% 100% F 100% F
Market Capitalization 3.58M 83% B 81% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.